Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model

Applied Health Economics and Health Policy

Volumn 11, Issue 1, 2013, Pages 53-63

  McEwan, Phil ^a   Kim, Ray ^b   Yuan, Yong ^c  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b Mayo Clinic   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; END STAGE LIVER DISEASE; HEALTH CARE COST; HEPATITIS C; HUMAN; LIVER FIBROSIS; PATIENT CARE; QUALITY OF LIFE; RESPONSE GUIDED THERAPY; SIMULATION; TREATMENT DURATION; UNITED KINGDOM;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GREAT BRITAIN; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL;

EID: 84873427421     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-012-0002-0     Document Type: Article

References (25)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74-81.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558-67.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35-46.
4. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer. 2008;98(7):1166-75.
5. Calvaruso V, Craxì A. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32(Suppl 1):2-8.
6. Harris RJ, Ramsay M, Hope VD, Brant L, Hickman M, Foster GR, et al. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health. 2012;22(2):187-92.
7. Health Protection Agency. Hepatitis C in the UK: 2011 Report. London: Health Protection Agency; 2011.
8. Schlütter J. Therapeutics: new drugs hit the target. Nature. 2011;474(7350):S5-7.
9. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, et al. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat. 2010;17(1):34-50.
10. Nakamura J, Kobayashi K, Toyabe SI, Aoyagi Y, Akazawa K. The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007;19(9):733-9.
11. Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011;15(17):i-xii, 1-210.
12. Nakamura J, Toyabe SI, Aoyagi Y, Akazawa K. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders. J Viral Hepat. 2008;15(4):293-9.
13. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418-31.
14. Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics. 2004;22(4):257-65.
15. Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol. 2004;99(8):1490-6.
16. Mangia A, Andriulli A. Tailoring the length of antiviral treatment for hepatitis C. Gut. 2010;59(1):1-5.
17. Pearlman BL. Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it. World J Gastroenterol. 2008;14(23):3621-7.
18. Cheng WSC, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol. 2010;53(4):616-23.
19. Joint Formulary Committee. British National Formulary. 60th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2010.
20. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2004;8(39):iii-iv, 1-125.
21. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2007;11(11):1-205, iii.
22. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49-57.
23. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol. 2011;106(1):38-45.
24. Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int. 2011;31(Suppl 1):18-22.
25. Ciesek S, Manns MP. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol. 2011;8(2):69-71.